Real-world Evidence Analytics Market (2022-2029)
The Real-world Evidence Analytics Market is expected to grow at a CAGR of 15.1% during the forecast period 2022–2029 to reach $2.93 billion by 2029.
- Published
- Jun 2022
- Pages
- 180
- Format
- PDF + Excel
- Report ID
- MRHC - 104620
- Base year
- 2021
- 2029 · FORECAST
- $2.93B
- 2029
- $2.93B
- CAGR 2022–2029
- 15.1%
2021 baseline · 2022–2029 forecast at 15.1% CAGR · hover a bar for the value
Key highlights
The Real-world Evidence Analytics Market is expected to grow at a CAGR of 15.1% during the forecast period 2022–2029 to reach $2.93 billion by 2029.
Pharmaceutical, Biotechnology, and Medical Device Companies Segment to Register the Largest Share in the RWE Analytics Market by 2029
North America is estimated to command the largest share of the global RWE analytics market in 2022, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2021 |
| Estimated Year | 2022 |
| Forecast Period | 2022–2029 |
| Market Size (2029) | USD 2.93 billion |
| CAGR (2022–2029) | 15.1% |
| Format | PDF, Excel & Cloud Portal · 180 pages |
| Segments Covered | By Application: Market Access & Reimbursement/Coverage Decisions, Drug Development & Approvals Oncology, Neurology, Immunology, Cardiovascular Diseases, Other Therapeutic Areas · By End User: Pharmaceutical, Biotechnology, and Medical Device Companies, Healthcare Payers, Healthcare Providers, Other End Users |
| Countries Covered | Europe (RoE), Asia-Pacific (RoAPAC) |
| Key Companies | ICON plc, IQVIA Holdings Inc. (U.S.), Oracle Corporation (U.S.), Parexel International Corporation (U.S.), PerkinElmer, Inc. (U.S.), PPD Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), Flatiron Health (U.S.) |
Report overview
Segments covered: application, end user. Regions: Europe, Asia-Pacific.
The report analyses various RWE analytics solutions offered by key companies for different applications, including market access & reimbursement/coverage decisions, drug development & approvals, post-market surveillance, medical device development & approvals, and clinical & regulatory decision-making. These solutions are used by various end users such as pharmaceutical, biotechnology, and medical device companies, healthcare payers, and healthcare providers. Rapidly-growing big data in healthcare, a shift from volume to value-based care, and a rising focus on personalized healthcare are the primary drivers for the growth of the RWE analytics market.
Report infographic
Market dynamics
1 factors across 1 forceAI Integration in RWE Analytics Current Trend in the Market
Data management & integration enhancements help improve the speed & quality of drug discovery and clinical trial processes. Artificial intelligence (AI) is employed in real-world data (RWD) to enhance data anomaly detection, standardization, and quality check at the pre-processing stage. AI is expected to offer pharma & biotech companies the ability to increase meaningful RWE output, decrease time to insights, and make the most of the available vast data sources. RWE technology platforms delivering smart data processing, analysis, and outcomes offer an unparalleled opportunity to capitalize on these computing advancements. When used as a part of a comprehensive RWE strategy, AI innovations can enhance drug development, improve patient treatment & access, and drive valuable new business opportunities.
Table of contents
11 chapters · 81 sections · 180 pages · click to expandSegmental analysis
| Segment | Largest share (2022) | Fastest growth (2022–2029) |
|---|---|---|
| By End User | Large market share of this | — |
By End User
- Pharmaceutical, Biotechnology, and Medical Device Companies Segment to Register the Largest Share in the RWE Analytics Market by 2029
- The pharmaceutical, biotechnology, and medical device companies segment is estimated to account for the largest share of the RWE analytics market in 2022.
- The large market share of this segment is mainly attributed to the increasing importance of RWE analytics in drug development & approvals, and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.
Geographic analysis
North America
Largest shareNorth America is estimated to command the largest share of the global RWE analytics market in 2022, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The rising burden of chronic diseases in the geriatric population, a shift towards value-based care, growing personalized healthcare, availability of electronic datasets, a well-developed healthcare industry, and rising big data in the healthcare sector are some of the major factors expected to drive the growth of this segment. North America to Dominate the Regional Market
Competitive landscape
- ICON plc · Ireland
- IQVIA Holdings Inc. (U.S.)
- Oracle Corporation (U.S.)
- Parexel International Corporation (U.S.)
- PerkinElmer, Inc. (U.S.)
- PPD Inc. (U.S.)
- SAS Institute Inc. (U.S.)
- UnitedHealth Group Incorporated (U.S.)
- Flatiron Health (U.S.)
Frequently asked questions
The global RWE analytics market covers the market sizes & forecasts of various RWE analytics solutions offered by the key market players to support pharmaceutical, biotechnology, and medical device companies, healthcare payers, healthcare providers, and other end users in making key decisions related to market access & reimbursement/coverage decisions, drug development & approvals, post-market surveillance, medical device development & approvals. The RWE analytics market studied in this report involves the value analysis of various segments and sub-segments of RWE analytics solution providers at regional and country levels.
Cite this report
Meticulous Research. (2022). Real-world Evidence Analytics Market - Global Opportunity Analysis And Industry Forecasts (2022-2029) (Report No. MRHC - 104620). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/real-world-evidence-analytics-market-5306